Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | GAA | P10253 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.57 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13454742 | 0.90 | MAPT (0.61) | ALDH1A1GAAHPGDKMT2AMEN1 | |
| SCHEMBL13454744 | 0.89 | LMNA (0.62) | ALDH1A1GAAHPGDKMT2AMEN1 | |
| SCHEMBL13453986 | 0.88 | LMNA (0.62) | ALDH1A1GAAHPGDKMT2AMEN1 | |
| SCHEMBL13454617 | 0.88 | POLB (0.59) | ALDH1A1GAAHPGDKMT2AMEN1 | |
| SCHEMBL13454491 | 0.87 | LMNA (0.60) | ALDH1A1GAAHPGDKMT2AMEN1 | |
| SCHEMBL13454743 | 0.87 | KMT2A (0.66) | ALDH1A1GAAHPGDKMT2AMEN1 | |
| SCHEMBL18606705 | 0.85 | CA1 (0.69) | ALDH1A1GAAHPGDKMT2AMEN1 | |
| SCHEMBL13453704 | 0.85 | POLB (0.81) | ALDH1A1GAAHPGDKMT2AMEN1 | |
| SCHEMBL16358462 | 0.84 | GPR55 (0.67) | ALDH1A1KMT2AMEN1GPR55LMNA | |
| SCHEMBL13454745 | 0.83 | POLB (0.56) | ALDH1A1GAAHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126938-B2 | Phosphatidylcholine transfer protein inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126938-B2 | Phosphatidylcholine transfer protein inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264756-A1 | Phosphatidylcholine Transfer Protein Inhibitors | PCTP, LCAT, CETP | ALDH1A1 4289/4885GAA 2398/4885HPGD 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.